. N-(3, 4-dimethoxycinnamoyl) an thranilic acid (tranilast), one of the anti allergic drugs, has been reported to inhibit the release of histamine and SRS-A from rat peritoneal exudate cells (PEC) and guinea-pig lungs in antigen-antibody reactions (5-11).
However, the mechanism of the inhibitory action of tranilast on the release of chemical mediators in immediate hypersensitivity reactions remains obscure.
In this study, to elucidate mechanisms of the inhibitory action of tranilast on the release of SRS-A, we investigated the effect of tranilast on the release of AA and its metabolites in rat PEC, rat purified mast cells (PMC) and human leucocytes and deter mined its effects on the activities of AA converting enzymes.
Materials and Methods
Preparation of rat PMC and PEC suspensions a) Rat PMC: Murine hybridoma secreting monoclonal IgE antibodies with anti-2, 4 dinitrophenyl (DNP) specificity was obtained by the fusion of X653Ag8 tumor cells and spleen cells from DNP-Ascaris-hyperimmu nized BALB/c mice. The supernatant of cul tured murine hybridoma gives a threshold reaction of passive cutaneous anaphylaxis (PCA) at a dilution of 1/2000 in rats. The supernatant was injected into the pleural and peritoneal cavities of male Wistar rats. After 16 hr, animals were exsanguinated by decapi tation, and the exudate cells were harvested from the pleural and peritoneal cavities with medium of the following composition: 150 mM NaCI, 3.7 mM KCI, 3.0 mM Na2HPO4. 12H20, 3.5 mM KH2PO4, 0.9 MM CaCl2' 2H2O, 5.6 mM glucose, 0.1% bovine serum albumin (BSA) and 5 units/ml heparin, pH 6.9. The cell suspension was centrifuged at 35xg for 10 min at 4°C and layered over 5.0 ml of a solution of 38% BSA as described by Sullivan et al. (12) . The cells were allowed to settle for 20 min and centrifuged at 460xg at room temp. for 20 min. Consequently , a mast cell population with a purity of approx . 90% was obtained from the BSA layer . b) Rat PEC: Male Wistar rats were killed by a blow on the head and exsanguination by decapitation.
Rat PEC suspension was pre pared as described by Nakazawa et al. (8) using a phosphate-buffered salt solution (PBS) containing 137 mM NaCI, 2.7 mM KCI, 1.8 mM CaCl2, 1.0 MM MgC12.6H2O , 5.6 mM glucose, 5 units/ml heparin and 5% (v/v) phosphate (0.1 M, 7.2). c) Human leucocytes: Ten ml of citrated blood from healthy humans were mixed with 2.0 ml of 4% dextran (M.W.=180000, Nakarai chemicals Kyoto, Japan) dissolved in 0.9% sodium chloride. The mixture was allowed to stand at room temp. for 1 hr, and then the upper phase of the mixture was washed 2 to 3 times with the PBS at 4°C. The leucocyte (neutrophil-lymphocyte :eosinophil: monocyte:basophi1=82:10:4:3:0:8) suspen sion was obtained from the phase. Release of SRS-A and PGs a) SRS-A assay: The rat PEC (containing 2-5 x 105 mast cells) and human leucocyte suspension was incubated at 37'C for 5 min before the addition of 0.5 and /ag/ml of ionophore A23187 (Calbiochem, San Diego, CA, U.S.A.), respectively, and then incubated for 10 min. The reaction mixture was cooled in ice and centrifuged at 180xg for 10 min to remove any sediment. An aliquot of the separated supernatant was applied to the isolated guinea-pig ileum in the presence of 10-7 g/ml of atropine and 10-6 g/ml of mepyramine. LTC4 release from rat PMC (containing 106 mast cells) by the addition of 300 ug/ml of DNP-Ascaris or 0.5 lug/ml of ionophore A23187 was measured using a Leukotriene C4-RIA Kit (New England Nuclear, Boston, MA, U.S.A.) b) PGs assay: The suspensions of PMC and PEC (both containing 3x105 mast cells) were incubated at 37°C for 10 min before the addition of 300 ug/ml of DNP-Ascaris and 0.5 fig/ml of ionophore A23187, re spectively, and then further incubated for 5 min. The reaction was stopped by 10-5 M of indomethacin and cooled in ice. PGE2 and 6-keto-PGE2a in the medium were ex tracted by the method of Inagawa et al. (13) and measured by radioimmunoassay (RIA). c) Histamine assay: The suspension of rat PMC (2-5x105 mast cells) was incubated at 37'C for 5 min before adding 300 fig/ml of DMP-Ascaris and then incubated for 20 min. The reaction mixture was cooled in ice and centrifuged. The separated supernatant was mixed with 4% of HC1O4 and boiled for 3 min. The mixture was then centrifuged and a clear supernatant was obtained. The histamine content was measured by the spectrofluoro metric assay of Shore et al. (14) . Release of 3H-AA and its 3H-metabolites Rat PMC (3x105) were incubated with 3H-AA (New England Nuclear , 10 fiCi/107 cells) for 30 min at 37'C. The labeled cell suspension was centrifuged at 35xg for 10 min 4°C and washed 3 times with the medium. After the equilibration for 30 min at 37°C, again, the cell suspension was centrifuged and washed as described above. Labeled rat PMC was preincubated and added with 300 fig/ml of DN P-Ascaris. The reaction was stopped with 10% TCA. The supernatant from the reaction mixture was extracted with ethanol and chloroform as described by Rouzer et al. (15) . The resulting organic solvent phase was dried by N2 gas, and the residue was developed by TLC using ethyl acetate : iso-octane : acetic acid : methanol water (90:50:20:20:100). The radioactivities of 3H-AA, 3H-PGE2, 3H-PGF2a and 3H-PGD2 on TLC were measured. Measurement of activities of 5-lipoxygenase, cyclooxygenase, PGI2 synthetase and glu tathione-S-transf erase 5-Lipoxygenase activities were measured using rat basophilic leukemia (RBL-1, Dai nippon seiyaku Laboratory Products, Suita, Japan) and 1-14C-AA as described by Jakschik and Lee (16) . The radioactivities of 14C-AA and 14C-5-hydroxyeicosatetraenoic (5-HETE) were measured for the estimation of 5-lipoxygenase activity.
Cyclooxygenase activity was followed as described by Yoshimoto et al. (17) . 1-14C AA (1 nmol, 5x104 cpm, New England Nuclear) and sheep vesicular gland micro somes (Ran Biochem., Tel Aviv, Israel) were incubated at 24°C for 1 min. The total radio activities of 14C-PGE2, 14C-PGF2a and 14C PGD2 produced were measured as cyclo oxygenase activity.
PGI2 synthetase activity was measured using rabbit aorta microsomes and 1-14C PGH2 which was produced from the reaction of 1-14C-AA and sheep vesicular gland microsomes, as described by Watanabe et al. (18) . The radioactivity of 6-keto-PGF1a pro duced was measured as described by Yoshi moto et al. (17) .
Glutathione-S-transferase activity was measured using human leucocytes which were prepared from the citrated blood and 4% dextran dissolved in 0.9% saline solution and LTA4 (Funakoshi, Tokyo, Japan) in the presence of 1 mM of glutathione. The ac tivity of LTC4 produced was bioassayed with the isolated guinea-pig ileum.
Test drugs
Tranilast (Kissei, Matsumoto, Japan), disodium cromoglycate (DSCG, Fujisawa, Osaka, Japan), aspirin (Sanko, Tokyo, Japan) and mepacrine (Sigma, St. Louis, MO, U.S.A.). Tranilast was dissolved in 1 % NaHCO3. DSCG and mepacrine was dis solved in the buffered solution. Aspirin was dissolved in 99.5% ethanol. These drugs were diluted to the required concentrations by the buffered solution. Test drugs were applied to rat PMC, rat PEC and human leucocytes 1 min before the addition of antigen or ion ophore A231 87. 
Results
Effect of tranilast on the SRS-A release: Figure 1 shows the inhibitory effect of tranilast and DSCG on the SRS-A release from rat PEC and human leucocytes by ionophore A23187. Tranilast at concentra tions of 10-5 to 10-3M suppressed the SRS A release from both preparations in a dose dependent manner. The IC50 (the concen tration which gives 50% inhibition) is approx. 10-4 M. However, DSCG hardly inhibited the SRS-A release from human leucocytes at concentrations of 10-6 to 10-3 M. Effect of tranilast and aspirin on the release of PGE2 and 6-keto-PGF1a: Figure  2 shows the inhibitory effect of tranilast on the release of PGE2 from sensitized rat PMC by 300 ,og/ml of DNP-Ascaris.
When the antigen was added, the release of PGE2 in creased 2.7 times compared with the spon taneous release without the antigen. Tranilast at a concentration of 10-3 M markedly inhibited the release of PGE2.
The release of PGE2 and 6-keto-PGF1r from rat PEC by 0.5 ,ug/ml of ionophore A23187 increased to 5 times in the former and 2 times in the latter compared with the spontaneous release without the ionophore ( Table 1) . As shown in Table 1 , tranilast at concentrations of 10-5 to 10-3 M inhibited the release of PGs in a dose-dependent manner, and 10-3 M of aspirin obviously suppressed it.
Effect of tranilast on the release of 3H-AA and its 3H-metabolites:
As shown in Fig. 3 , the release of 3H-AA, 3H-PGE2, 3H-PGF2a and 3H-PGD2 from sensitized rat PMC by DNP-Ascaris markedly increased compared with the spontaneous release. Tranilast (10-5 10-3 M), DSCG (10-5-10-4 M) and mepacrine (10-3 M) obviously inhibited the releases of 3H-AA and Its 3H-metabolites.
Effect of tranilast on the activities of 5 lipoxygenase, cyclooxygenase, PG12 syn thetase and glutathione-S-transferase: Figure  4 shows the effect of tranilast on the activities of 5-lipoxygenase, cyclooxygenase, PG12 synthetase and glutathlone S-transferase. Tranilast hardly affected the activities of these enzymes at concentrations of 10-5 to 10-3 M. The time course of release of histamine and LTC4: As shown in Fig. 5 , the histamine release from rat PMC by ionophore A23187, initiated prior to LTC4 release, reached ap prox. maximum level at 1 min after the addi tion of ionophore. On the other hand, that of LTC4 reached maximum at 5 min. Similar results were obtained during antigen-anti body reactions using sensitized rat PMC (data not shown). Table 1 . Effects of tranilast and aspirin on the release of arachidonic acid metabolites (PGE2 and 6 keto-PGF,a) from the rat peritoneal exudate cells Discussion SRS-A, oxidative metabolites of AA, is composed of LTC4, LTD4 and LTE4. AA dis sociated by the action of phospholipase A2 from mast cell membrane phospholipid is metabolized by two major enzyme systems. The 5-lipoxygenase pathway eventually leads to the production of LTE4, one of the most potent chemotactic molecules known, and SRS-A containing LTC4, LTD4 and LTE4, while the cyclooxygenase pathway is re sponsible for the production of primary PGs, thromboxanes and prostacyclin (precursor of 6-keto-PGF1a).
Tranilast suppressed SRS A release from rat PEC and human leucocytes by the addition of ionophore A231 87 in a dose-dependent manner. In addition, pros taglandins (PG E2 and/or 6-keto-PGF1a), released by the addition of antigen and ionophore A23187, was markedly inhibited by tranilast in rat PEC and PMC. The release of labeled AA incorporated into mast cells was suppressed by tranilast and mepacrine (phospholipase A2 inhibitor). Tranilast had no effect on activities of AA-converting enzymes such as 5-lipoxygenase, cyclo oxygenase, glutathione-S-transferase and PG 12 synthetase.
From these results, we speculate that tranilast may suppress the dis sociation ofAAfrom membrane phospholipids. Vertical bars show the standard errors of the mean. *, ** and ***: significant difference from the control at P<0.05, P<0.01 and P<0.001, respectively. In a previous study (8) , however, tranilast did not significantly inhibit the activity of phospholipase A2 even at a concentration of 10-3 M. From these results, we suggest that the mechanism for the inhibitory action of tranilast on AA metabolism may be related to a process occurring before the dissociation of AA which is cleaved from membrane phospholipids.
Attention has been given to SRS-A and PGs as substances capable of modulating antigen-induced histamine release in a number of systems. The effect of AA and its metabolites on the histamine release from mast cells or basophils has been reported (19) (20) (21) (22) (23) (24) (25) .
PGD2 preferentialy released from mast cells by the addition of antigen and ionophore (26) does not have any influence on the histamine release (19) . The PGE and PGF series do not have an inhibitory effect on the histamine release (20) . In addition, indomethacin, a cyclooxygenase inhibitor, suppresses
PGs production but has no in fluence on the histamine release from rat mast cells and basophil leukemia (RBL)-2H; conversely, it enhances the histamine release in human basophils (21, 22) . On the other hand, eicosatetraynoic acid (ETYA) which blocks both lipoxygenase and cyclo oxygenase inhibits the histamine release from rat mast cells and human leucocytes (23) (24) (25) .
The phospholipase A2 inhibitors suppress production of AA and its me tabolites and result in a decrease in histamine release (27, 28) . The suppression of chemical mediator release by phospholipase A2 inhi bitors seems to be due to an indirect sup pression of a lipoxygenase pathway through the inhibition of phospholipase A2 activity . However, LTC4 and LTD4 have no influence on the histamine release (23, 25) . In addition , neither the IgE-dependent release of SRS-A nor ionophore-induced SRS-A release initiate until the histamine release is almost complete (reference 1 and Fig. 5 ). Therefore, it is unlikely that metabolites catalyzed through the 5-lipoxygenase pathway as well as the cyclooxygenase pathway from AA are in volved in the mechanisms of the histamine release from mast cells.
We demonstrated that tranilast at the same concentration inhibits the release of SRS-A and PGs not only in the antigen-antibody reaction but also in non-immunological stimulation.
The concentration required to inhibit mediator release of tranilast in the present study coincides with that used in the previous studies in which the drug sup presses IgE-dependent histamine or SRS-A release from rat PEC and guinea-pig lung (5 11) . Therefore, we assume that tranilast inhib its via a common process or through the same process in the release of chemical mediators from mast cells.
It is noted that intracellular cyclic AMP and Ca ion mobilization play an important role in release of chemical mediators (1) . Therefore, we think that it is necessary to investigate the effect of tranilast on cyclic AMP and Ca ion of mast cells in the future.
